Z wytycznych grupy SWENOTECA:
8.2.5 Post-chemotherapy residual masses seminoma
Seminomatous tumours are often characterised by a slow regression rate after chemotherapy. Residual tumours mostly consist of fibrotic or necrotic tissue; however, in up to 30 % of cases residual tumours > 3 cm contained germ-cell malignancy (79-81). In post-chemotherapy seminoma residual lesions, a FDG-PET scan has a high negative predictive value (95%) and is excellent for the exclusion of active disease in lesions ≥ 3 cm (82).
It should not be performed earlier than 9 weeks after day 1 of the last chemotherapy course, due to the risk of false positivity. FDG-PET can contribute to the management of residual seminoma lesions, especially in terms of avoiding
unnecessary additional treatment for patients with non-regressing lesions ≥ 3 cm (83).
In post-chemotherapy seminoma residual lesions, a FDG-PET has a low positive predictive value (23%) for germ-cell malignancy (84). Thus, repeated FDG-PET imaging and biopsy should be considered in case of a positive FDG-PET in this situation. • Consolidating treatment after chemotherapy (surgery or radiotherapy) should not be applied routinely
• Regressing or persisting residual mass < 3 cm: Monitor with an appropriate radiological method (MRI, CT) and serum tumour markers • Residual mass ≥ 3 cm and not regressing: FDG-PET scan is recommended, not earlier than 9 weeks from day 1 of the last chemotherapy course
• Stable residual mass and negative FDG-PET scan: Continue follow-up
• Stable residual mass and positive FDG-PET scan: Repeated FDG-PET after 6-8 weeks and biopsy before consolidating therapy is decided upon
- Germ-cell malignancy: Surgery, if feasible
- Germ-cell malignancy and surgery not feasible: Radiotherapy to limited fields to a total dose of 40 Gy in 2 Gy fractionshttps://pro-ebp.awf-bp.edu.pl/glosarius ... cyjna-dwp/Jutro macie konsultacje z prof. O wszystko będziecie mogli się zapytać.